CS Pramesh, MS, FRCS, on Opportunities in India: A Perspective From a Low-Middle Income Country

First International Summit on Interventional Pharmacoeconomics

David A. Hyman, MD, JD, on Inclusive Shared Savings

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Cutting Cancer Care Costs With Alternative Pharmacologic Options

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, of Emory University, discusses the ways in which clinical pharmacology can help yield cost savings without sacrificing efficacy by, for example, altering regimens to extend drug supplies, lowering doses, dosing less frequently, or shortening the duration of treatment.

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Amit Sanyal, MD: A Clinician’s Perspective

Mar

Today In Oncology

CS Pramesh, MS, FRCS, on Opportunities in India: A Perspective From a Low-Middle Income Country

Related Videos

David A. Hyman, MD, JD, on Inclusive Shared Savings

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Cutting Cancer Care Costs With Alternative Pharmacologic Options

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Amit Sanyal, MD: A Clinician’s Perspective

Dynamic Accessible Risk Stratification Tool Created for Smoldering Multiple Myeloma

Early Results Demonstrate Safety and Efficacy of Mutant Calreticulin–Specific Monoclonal Antibody in Myelofibrosis

Pembrolizumab With or Without Lenvatinib in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

AI Model for Predicting Oncotype DX 21-Gene Recurrence Score

Breast Cancer Recurrence Remains Low Even After 10 Years With Radiotherapy Tailored to Patient’s Individual Risk